Compare Vanguard Information Technology Index Fund ETF (VGT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Information Technology Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Information Technology Index Fund ETF trades at $128.1 (market cap $170.20B), while State Street SPDR S&P Biotech ETF trades at $153.7 (market cap $10.11B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 16.8× State Street SPDR S&P Biotech ETF's market cap, and Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Information Technology Index Fund ETF for 129 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VGT | XBI | |
|---|---|---|
Market Cap | $170.20B | $10.11B |
Volume | 5,132,883 | 12,903,266 |
52-Week High | $129.79 | $169.55 |
52-Week Low | $83.59 | $104.99 |
Typical Hold Time | 129 Days | 38 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VGT trades at $127.98, down 1.07% on the day, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights its strong historical performance and appeal for long-term growth, with a focus on technology sector exposure. The ETF's low expense ratio and concentration in top tech names like Nvidia, Apple, and Microsoft are key attractions.
Outlook remains positive given tech sector momentum, but risks include high concentration in a few stocks and sensitivity to AI growth trends. Dividend yield is minimal, emphasizing capital appreciation over income. Investors should weigh sector volatility against long-term growth potential.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
